OBJECTIVES: The contribution of individual immune response to Staphylococcus aureus bacteremia on outcome has not been well studied. The objective was to relate the host cytokine response to outcome of Staphylococcus aureus bacteremia. DESIGN: Prospective observational study. SETTING: Three U.S. university-affiliated medical centers. PATIENTS: Adult patients infected with Staphylococcus aureus bacteremia hospitalized between July 2012 and August 2014. INTERVENTIONS: Blood specimens were obtained at Staphylococcus aureus bacteremia onset and 72 hours after therapy initiation. Levels of tissue necrosis factor, interleukin-6, interleukin-8, interleukin-17A, and interleukin-10 were measured by enzyme-linked immunosorbent assay at each time point and compared between those with persistent bacteremia (≥ 4 d) and resolving bacteremia. Primary outcome was persistent bacteremia after 4 days of effective therapy. Secondary outcomes were 30-day mortality and 30-day recurrence. MEASUREMENTS AND MAIN RESULTS: A total of 196 patients were included (mean age, 59 yr); of them, 33% had methicillin-resistant Staphylococcus aureus bacteremia. Forty-seven percent of the methicillin-resistant Staphylococcus aureus strains were staphylococcal cassette chromosome mec IV. Persistent bacteremia occurred in 24% of patients (47/196); they were more likely to die than resolving bacteremia group (28% vs 5%; p < 0.001). Compared with resolving bacteremia group, persistent bacteremia patients had higher initial median levels of tissue necrosis factor (44.73 vs 21.68 pg/mL; p < 0.001), interleukin-8 (124.76 vs 47.48 pg/mL; p = 0.028), and interleukin-10 (104.31 vs 29.72 pg/mL; p < 0.001). Despite 72 hours of treatment, levels remained higher for the persistent bacteremia group than for the resolving bacteremia group (tissue necrosis factor: 26.95 vs 18.38 pg/mL, p = 0.02; interleukin-8: 70.75 vs 27.86 pg/mL, p = 0.002; interleukin-6: 67.50 vs 21.81 pg/mL, p = 0.005; and interleukin-10: 30.98 vs 12.60 pg/mL, p < 0.001). Interleukin-17A levels were similar between groups at both time points. After controlling for confounding variables by multivariate analysis, interleukin-10/tissue necrosis factor ratio at 72 hours most significantly predicted persistence (odds ratio, 2.98; 95% CI, 1.39-6.39; p = 0.005) and mortality (odds ratio, 9.87; 95% CI, 2.64-36.91; p < 0.001) at values more than 1.00 and more than 2.56, respectively. CONCLUSIONS: Sustained elevation of interleukin-10/tissue necrosis factor ratio at 72 hours suggests a dysregulated immune response and may be used to guide management to improve outcomes.
OBJECTIVES: The contribution of individual immune response to Staphylococcus aureus bacteremia on outcome has not been well studied. The objective was to relate the host cytokine response to outcome of Staphylococcus aureus bacteremia. DESIGN: Prospective observational study. SETTING: Three U.S. university-affiliated medical centers. PATIENTS: Adult patients infected with Staphylococcus aureus bacteremia hospitalized between July 2012 and August 2014. INTERVENTIONS: Blood specimens were obtained at Staphylococcus aureus bacteremia onset and 72 hours after therapy initiation. Levels of tissue necrosis factor, interleukin-6, interleukin-8, interleukin-17A, and interleukin-10 were measured by enzyme-linked immunosorbent assay at each time point and compared between those with persistent bacteremia (≥ 4 d) and resolving bacteremia. Primary outcome was persistent bacteremia after 4 days of effective therapy. Secondary outcomes were 30-day mortality and 30-day recurrence. MEASUREMENTS AND MAIN RESULTS: A total of 196 patients were included (mean age, 59 yr); of them, 33% had methicillin-resistant Staphylococcus aureus bacteremia. Forty-seven percent of the methicillin-resistant Staphylococcus aureus strains were staphylococcal cassette chromosome mec IV. Persistent bacteremia occurred in 24% of patients (47/196); they were more likely to die than resolving bacteremia group (28% vs 5%; p < 0.001). Compared with resolving bacteremia group, persistent bacteremiapatients had higher initial median levels of tissue necrosis factor (44.73 vs 21.68 pg/mL; p < 0.001), interleukin-8 (124.76 vs 47.48 pg/mL; p = 0.028), and interleukin-10 (104.31 vs 29.72 pg/mL; p < 0.001). Despite 72 hours of treatment, levels remained higher for the persistent bacteremia group than for the resolving bacteremia group (tissue necrosis factor: 26.95 vs 18.38 pg/mL, p = 0.02; interleukin-8: 70.75 vs 27.86 pg/mL, p = 0.002; interleukin-6: 67.50 vs 21.81 pg/mL, p = 0.005; and interleukin-10: 30.98 vs 12.60 pg/mL, p < 0.001). Interleukin-17A levels were similar between groups at both time points. After controlling for confounding variables by multivariate analysis, interleukin-10/tissue necrosis factor ratio at 72 hours most significantly predicted persistence (odds ratio, 2.98; 95% CI, 1.39-6.39; p = 0.005) and mortality (odds ratio, 9.87; 95% CI, 2.64-36.91; p < 0.001) at values more than 1.00 and more than 2.56, respectively. CONCLUSIONS: Sustained elevation of interleukin-10/tissue necrosis factor ratio at 72 hours suggests a dysregulated immune response and may be used to guide management to improve outcomes.
Authors: Benjamin P Howden; Paul D R Johnson; Peter B Ward; Timothy P Stinear; John K Davies Journal: Antimicrob Agents Chemother Date: 2006-09 Impact factor: 5.191
Authors: Kristin K Bonnstetter; Daniel J Wolter; Fred C Tenover; Linda K McDougal; Richard V Goering Journal: J Clin Microbiol Date: 2006-11-08 Impact factor: 5.948
Authors: P C Hill; M Birch; S Chambers; D Drinkovic; R B Ellis-Pegler; R Everts; D Murdoch; S Pottumarthy; S A Roberts; C Swager; S L Taylor; M G Thomas; C G Wong; A J Morris Journal: Intern Med J Date: 2001-03 Impact factor: 2.048
Authors: Scott C Brakenridge; Philip A Efron; Julie A Stortz; Teczan Ozrazgat-Baslanti; Gabriela Ghita; Zhongkai Wang; Azra Bihorac; Alicia M Mohr; Babette A Brumback; Lyle L Moldawer; Frederick A Moore Journal: J Trauma Acute Care Surg Date: 2018-08 Impact factor: 3.313
Authors: Alessander O Guimaraes; Yi Cao; Kyu Hong; Oleg Mayba; Melicent C Peck; Johnny Gutierrez; Felicia Ruffin; Montserrat Carrasco-Triguero; Jason B Dinoso; Angelo Clemenzi-Allen; Catherine A Koss; Stacey A Maskarinec; Henry F Chambers; Vance G Fowler; Amos Baruch; Carrie M Rosenberger Journal: Clin Infect Dis Date: 2019-04-24 Impact factor: 9.079
Authors: Warren E Rose; Sanjay K Shukla; Andrew D Berti; Mary S Hayney; Kelsey M Henriquez; Andrea Ranzoni; Matthew A Cooper; Richard A Proctor; Victor Nizet; George Sakoulas Journal: Clin Infect Dis Date: 2017-05-15 Impact factor: 9.079
Authors: Dijoia B Darden; Frederick A Moore; Scott C Brakenridge; Eduardo B Navarro; Stephen D Anton; Christiaan Leeuwenburgh; Lyle L Moldawer; Alicia M Mohr; Philip A Efron; Robert T Mankowski Journal: Crit Care Clin Date: 2020-10-28 Impact factor: 3.598
Authors: Emily M Eichenberger; Felicia Ruffin; Michael Dagher; Reginald Lerebours; Sin-Ho Jung; Batu Sharma-Kuinkel; Andrew N Macintyre; Joshua T Thaden; Matthew Sinclair; Lauren Hale; Celia Kohler; Scott M Palmer; Barbara D Alexander; Vance G Fowler; Stacey A Maskarinec Journal: Am J Transplant Date: 2020-11-20 Impact factor: 9.369
Authors: Travis B Nielsen; Paul Pantapalangkoor; Jun Yan; Brian M Luna; Ken Dekitani; Kevin Bruhn; Brandon Tan; Justin Junus; Robert A Bonomo; Ann Marie Schmidt; Michael Everson; Frederick Duncanson; Terence M Doherty; Lin Lin; Brad Spellberg Journal: mBio Date: 2017-08-22 Impact factor: 7.867
Authors: Jared A Greenberg; Cara L Hrusch; Mohammad R Jaffery; Michael Z David; Robert S Daum; Jesse B Hall; John P Kress; Anne I Sperling; Philip A Verhoef Journal: Crit Care Date: 2018-04-25 Impact factor: 9.097